Nektar Therapeutics (NKTR) Fundamental Analysis: Revenue, Earnings & Valuation

2.90 / 10

Underperform

Fundamentals score 2.9/10, rated Underperform. Interest coverage is healthy, yet revenue growth is sharply negative and long‑term debt relative to working capital is high. Revenue‑MV is modestly positive, but overall financial health warrants caution.

Analysis Checks(5/10)

Revenue-MV

Value-3.63

Score3/3

Weight41.31%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-43.89

Score1/3

Weight-1.62%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.71%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value28.09

Score3/3

Weight7.67%

1M Return1.67%

PB-ROE

Value26.99

Score1/3

Weight33.38%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.64

Score1/3

Weight-2.78%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.79%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-43.89

Score1/3

Weight-1.27%

1M Return-0.30%

Cost of sales ratio (%)

Value0.00

Score2/3

Weight-4.53%

1M Return-1.13%

Asset-MV

Value-0.55

Score1/3

Weight37.32%

1M Return6.31%

Is NKTR fundamentally strong?

NKTR scores 2.90/10 on fundamentals and holds a Premium valuation at present. Backed by its -217.94% ROE, -297.07% net margin, -12.58 P/E ratio, 22.98 P/B ratio, and -12.10% earnings growth, these metrics solidify its Underperform investment rating.